Nazanin Janfaza
Overview
Explore the profile of Nazanin Janfaza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
SeyedAlinaghi S, Janfaza N, Mirzapour P, Siami H, Ali Z, Matini P, et al.
Curr HIV Res
. 2024 Jan;
22(1):16-26.
PMID: 38279732
Objective: This article aimed to analyze upper endoscopic findings in the HIV patient population to elucidate the upper-gastrointestinal complications related to HIV infection. Gastrointestinal (GI) disorders in individuals living with...
2.
SeyedAlinaghi S, Karimi A, Pashaei Z, Shobeiri P, Janfaza N, Behnezhad F, et al.
Infect Disord Drug Targets
. 2023 Apr;
23(5):e130423215723.
PMID: 37069717
Introduction: SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission...
3.
Mehraeen E, Karimi A, Mirghaderi P, Mirzapour P, Pashaei Z, Qaderi K, et al.
Infect Disord Drug Targets
. 2023 Jan;
23(4):e200123212975.
PMID: 36683317
Introduction: Earlier studies demonstrated a decreased level of physical activity (PA) during the COVID-19 pandemic. Therefore, we aimed to systematically review the relevant studies among various age groups and explore...
4.
SeyedAlinaghi S, Karimi A, Mojdeganlou H, Pashaei Z, Mirzapour P, Shamsabadi A, et al.
SAGE Open Med
. 2022 Aug;
10:20503121221115053.
PMID: 35983085
Objective: Understanding the minimum infective dose is significant for risk assessment in the performance of suitable infection control strategies in healthcare centers. However, the literature lacks strong evidence regarding this...
5.
SeyedAlinaghi S, Karimi A, Barzegary A, Pashaei Z, Afsahi A, Alilou S, et al.
Health Sci Rep
. 2022 Mar;
5(2):e529.
PMID: 35252593
Introduction: Several reports previously described mucormycosis co-infection in patients with COVID-19. As mucormycosis and COVID-19 co-infection might adversely affect patients' outcomes, we aimed to systematically review the related evidence and...
6.
SeyedAlinaghi S, Karimi A, Mojdeganlou H, Alilou S, Mirghaderi S, Noori T, et al.
Health Sci Rep
. 2022 Feb;
5(2):e00516.
PMID: 35224217
Background And Aims: Scientists and healthcare workers have expressed their concerns on the impacts of the COVID-19 pandemic on vaccination coverage in children and adolescents. Therefore, we aimed to systematically...
7.
Dadras O, Afsahi A, Pashaei Z, Mojdeganlou H, Karimi A, Habibi P, et al.
Immun Inflamm Dis
. 2021 Dec;
10(3):e580.
PMID: 34904379
Introduction: Patients with COVID-19 may present different viral loads levels. However, the relationship between viral load and disease severity in COVID-19 is still unknown. Therefore, this study aimed to systematically...
8.
Esfahanian F, SeyedAlinaghi S, Janfaza N, Tantuoyir M
SAGE Open Med
. 2021 Oct;
9:20503121211051573.
PMID: 34676075
Objective: The coronavirus disease 2019 (COVID-19) has become a global pandemic. Timely and effective predictors of survival and death rates are crucial for improving the management of COVID-19 patients. In...
9.
Mehraeen E, Mehrtak M, Janfaza N, Karimi A, Heydari M, Mirzapour P, et al.
J Diabetes Sci Technol
. 2021 Apr;
16(4):1008-1015.
PMID: 33840235
Introduction: Mobile-based applications play a leading role in changes in life-style, improve medication adherence, and provide a unique opportunity to aid patients with type 2 diabetes mellitus (T2DM) elevate their...